CSTI-300; a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome

American Society for Pharmacology and Experimental Therapeutics (ASPET), The Journal of Pharmacology and Experimental Therapeutics, 1(373), p. 122-134, 2020

Journal article published in 2020 by Alexander Roberts, Gillian Grafton, Andrew D. Powell, Kristian Brock, Chunlin Chen, Dejian Xie, Jinkun Huang, Shuang Liu, Alison J. Cooper, Catherine A. Brady, Omar Qureshi, Zania Stamataki, David D. Manning, Nicholas A. Moore, Bruce J. Sargent and other authors.

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving forbidden

Published version: archiving forbidden

Policy details

Data provided by